|Bladder Cancer||Benign Prostatic Hyperplasia (BPH)|
|Erectile Dysfunction (ED)||Hypogonadism|
|Kidney Cancer||Kidney Stones|
|Overactive Bladder||Premature Ejaculation|
|Prostate Cancer||Prostate Specific Antigen (PSA)|
|Reproductive Medicine||Urinary Incontinence|
|Urinary Tract Infections (UTI)|
Men with diabetic peripheral neuropathy have an increased occurrence of erectile dysfunction and lower-urinary-tract symptoms.
Urologic complications requiring hospital admission grew from 3.6% in 2000 to 3.9% in 2008, largely because of infections.
Patients are 28% more likely to have partial nephrectomy at hospitals offering robotic-assisted surgery.
The condition is more likely in men with chronic bacterial prostatitis caused by C. trachomatis rather than other uropathogens.
Men who had PSA relapse after receiving post-radical surgery salvage radiation therapy had a median overall survival of nearly 14 years.
The latest model is longer than the previous version, such that it "awkwardly juts out" when stored in the breast pocket.
Most stones patients do not need additional imaging with computed tomography, study finds.
Radiotherapy given within 6 months of radical prostatectomy reduces cancer-specific mortality in men with highly aggressive disease.
Joint committee also calls for drug makers to run heart-risk tests on popular 'Low T' products.
FDA has approved a supplemental new drug application for Stendra (avanafil) taken early as ~15 minutes before sexual activity.
High rates of preserved sexual function with combination beam plus brachytherapy.
Utilization rates jumped by double digits across prostate cancer risk groups from 2004 to 2011.
American College of Physicians guidelines addresses nonsurgical management of urinary incontinence in women.
Men with male pattern baldness may face a higher risk of aggressive prostate cancer.
This benefit is not seen in patients who undergo radical prostatectomy, according to an updated meta-analysis.
Black prostate cancer patients more likely to develop aggressive disease earlier than white patients.
Low-dose aspirin decreased the likelihood of acute genitourinary toxicity in prostate cancer by 27%.
Enzalutamide and abiraterone may not benefit men with metastatic castration-resistant prostate cancer who have AR-V7 in circulating tumor cells.
However, they are more likely to die from causes other than prostate cancer than men with normal metabolic levels.
The drug is now also approved for use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.